Medipost Co. | Date: 2017-03-29
Provided are a composition for preventing hair loss and stimulating hair growth, which includes small-sized stem cells, particularly, small-sized stem cells having a diameter of 8 m or less, or a conditioned medium thereof as an active ingredient, a method of preparing the same, and a use of the same. Provided is a use of the composition utilizing a hair growth stimulating function of the small-sized stem cells having a diameter of 8 m or less to considerably increase activity of hair follicle stem cells in a telogen phase.
News Article | May 9, 2017
WASHINGTON, DC--(Marketwired - May 9, 2017) - The Alliance for Regenerative Medicine (ARM) today released the agenda for the inaugural Cell & Gene Exchange, the only partnering conference that brings together the regulatory, business and patient advocacy communities across the cell and gene therapy sectors. Co-produced by ARM and EBD Group and held in partnership with Global Genes, the event will take place May 22 and 23 in Washington, D.C. "Our industry is on the cusp of some truly remarkable achievements, including some of the first significant sector product approvals," said Morrie Ruffin, managing director of ARM. "With these anticipated near-term milestones in mind, this event provides attendees timely regulatory and commercial content, as well as numerous business development and partnering opportunities." This first-ever Cell & Gene Exchange provides access to more than 200 potential partners across the field, enabling attendees to connect directly with drug development companies, manufacturers, investors and patient groups. The event also features presentations by 16 leading therapeutic developers and patient advocacy organizations, as well as numerous panels and roundtables offering insights from industry leaders on current trends in dealmaking, critical development benchmarks, commercialization, regulatory and reimbursement updates and more. Presenting Companies: Abeona Therapeutics, Asymmetrex, bBHC-STRI, Be the Match, Biostage, BrainStorm Cellular Therapeutics, Calimmune, Cellular Dynamics International, Cesca Therapeutics, Fibrocell, Genethon, MEDIPOST, ORIG3N, Research Cancer Institute of America, Sigilon and Universal Cells The event's most up-to-date agenda is available here. Additional speakers and presenting companies will be added in the coming weeks. Registration includes access to the ARM Annual Dinner on May 23 at the Willard InterContinental Hotel in Washington, D.C. This intimate dinner celebrates the field's major accomplishments over the past year, recognizing key corporate, scientific and policy leaders in the sector, including members of Congress, patient advocates, disease-foundation executives and other industry champions. The Cell & Gene Exchange will take place May 22 & 23, 2017 at the Ronald Reagan Building, 1300 Pennsylvania Avenue NW, Washington, D.C. 20004. For more information about the Cell & Gene Exchange and to register, please visit the event website here. For members of the media interested in attending, please contact Lyndsey Scull, firstname.lastname@example.org. About The Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
Medipost Co. | Date: 2013-08-19
A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases.
Medipost Co. | Date: 2013-09-02
Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.
Medipost Co. | Date: 2012-11-19
Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO- and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs.
Medipost Co. | Date: 2013-06-19
Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.
Medipost Co. | Date: 2014-07-09
An exemplary embodiment of the present invention provides TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and applications thereof.
Medipost Co. | Date: 2015-03-02
Provided are a composition for preventing hair loss and stimulating hair growth, which includes small-sized stem cells, particularly, small-sized stem cells having a diameter of 8 m or less, or a culture thereof as an active ingredient, a method of preparing the same, and a use of the same. Provided is a use of the composition utilizing a hair growth stimulating function of the small-sized stem cells having a diameter of 8 m or less to considerably increase activity of hair follicle stem cells in a telogen phase.
MEDIPOST Co. | Date: 2015-07-06
Provided is an a composition for preventing hair-loss and promoting hair growth containing as an active ingredient conditioned media of stem cells stimulated by particular hair catagen inducers including TGF-, a method of manufacturing the same, and a use thereof. In particular, the present invention relates to a use of the function of very effective hair growth by secreting Wnt3a, Bcl-2, CyclinD-1 and the like, which are known as signal transduction proteins.
Medipost Co. | Date: 2014-08-29
A method for culturing mesenchymal stem cells. The method includes isolating mesenchymal stem cells having a size of 8 m or less and culturing the mesenchymal stem cells in a medium containing calcium and magnesium and under a low oxygen condition. The method can significantly improve the proliferative capacity and differentiation potential of the mesenchymal stem cells.